SummaryThe novel CCK-A agonist, (S)-3-(3-f1-[(isopropylphenylcarbamoyl)methyl]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo [b][1,4]diazepin-3-ylgureido)benzoic acid, GI181771 ((S)-1) has been isotopically labelled with carbon-11 at its urea site using [ 11 C]phosgene in a one-pot two-step process, via the intermediate preparation of an specific radioactivities ranging from 500 to 1500 mCi/mmol (18.5-55.5 GBq/mmol). The radiotracer preparation was a clear and colourless solution and its pH was between 5 and 7. As demonstrated by HPLC analysis, the radiolabelled product was found to be >99% chemically and radiochemically pure and the preparation was shown to be free of non-radioactive precursors (starting amines) and radiochemically stable for at least 60 min. Finally, enantiomeric purity was found to be >99%